 The U.S. Food and Drug Administration FDA has accepted a supplemental Biologics License Application sBLA for review submitted by Regeneron Pharmaceuticals NASDAQ: REGN and Sanofi NASDAQ: SNY for the lead drug candidate Dupixent dupilumab for the treatment of patients with prurigo. 